A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

NCT00508157 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

125

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Accrual

Conditions

Metabolic Syndrome
Schizophrenia

Interventions

DRUG: Aripiprazole
DRUG: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]